PeptiDream
4587.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥2.8bn | ¥31.3bn | ¥12.7bn | ¥15.4bn | ¥9.4bn | ¥11.7bn |
| Operating income | −¥5.3bn | ¥21.0bn | ¥6.4bn | ¥9.1bn | ¥4.4bn | — |
| Ordinary income | −¥5.3bn | ¥20.5bn | ¥6.4bn | ¥8.8bn | ¥4.8bn | ¥7.0bn |
| Total assets | ¥70.1bn | ¥89.7bn | ¥68.2bn | ¥55.2bn | ¥26.6bn | ¥26.3bn |
| Net assets / equity | ¥49.4bn | ¥55.6bn | ¥40.6bn | ¥29.4bn | ¥25.0bn | ¥21.2bn |
| Operating cash flow | — | — | — | — | ¥6.7bn | ¥1.7bn |
| EPS (basic) | ¥-41.93 | ¥162.6 | ¥44.85 | ¥33.11 | ¥27.98 | ¥35.4 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 17
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 89 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 213 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 91 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 223 figures · EDINET |
| 2023-01-01 → 2023-12-31 | AnnualAmended | 226 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 91 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 91 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 226 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 115 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2Amended | 115 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1Amended | 88 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 115 figures · EDINET |
| 2022-01-01 → 2022-12-31 | AnnualAmended | 218 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 88 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 218 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 117 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 117 figures · EDINET |
23 more reports are still being processed.
Segments · FY ended 2025-12
| Segment | External sales | Profit |
|---|---|---|
| Drug Discovery And Development Business | ¥2.8bn | −¥5.4bn |
| Radiopharmaceuticals Business | ¥15.7bn | ¥435m |
| Adjustments & eliminations | — | — |
| Total | ¥18.5bn | −¥4.9bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.